What Happened?
Redwood City, CA-based Adverum Promoted Christopher DeRespino as Acting Chief Financial Officer and Chief Business Officer
About the Company
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.
About the Person
Christopher DeRespino is Acting Chief Financial Officer and Chief Business Officer at Adverum. Previously, Christopher held various senior HR leadership roles in the industry.
Info Source
News
Short Profile